Charles Van Clevenger, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Northwestern University, Feinberg School of Medicine - Chicago IL
Rank: Full Professor
Years: 2005-2013

Virginia Commonwealth University School Of Medicine (Previously MCV) - Richmond VA
Rank: Full Professor
Years: 2013-present

None Reported

The transactivating properties of nuclear prolactin receptor are mediated through its inducible interaction with the chromatin associated protein, HMGN2.
Molecular Endocrinology
Volume: 25
Date: 08 2011

The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
American Journal of Pathology
Volume: 182
Date: 01 2013

Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling
Cell Communication and Signaling
Volume: 13
Date: 01 2015

HDAC6 deacetylates HMGN2 to regulate Stat5a activity and breast cancer growth.
Molecular Cancer Research
Volume: 14
Date: 01 2016

Phosphorylation of Nek3 kinase at threonine 165 in its activation segment contributes to breast cancer cell migration
Journal of Biological Chemistry
Volume: 291
Date: 01 2016

A pilot study of cabergoline for the treatment of metastatic breast cancer.
Breast Cancer Research and Treatment
Volume: 165
Date: 01 2017

Histone H1 and HMGN2 regulate prolactin-induced Stat5 recruitment and function in breast cancer cells.
Journal of Biological Chemistry
Volume: 292
Date: 01 2017

Cyclophilin A impacts Jak2/Stat5 signaling, morphogenesis, differentiation and tumorigenesis in the mammary gland
Cancer Research
Volume: 78
Date: 12 2018

The inhibition of cyclophilin A by NIM811 regulates PRLr/Jak2 complex signaling, mammary tumorigenesis and metastases. iScience, 23:101581, 2020.
iScience
Volume: 23
Date: 08 2020

The human intermediate prolactin receptor is a mammary proto-oncogene.
Nature (npj) Breast Cancer
Volume: 7
Date: 03 2021